<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00209833</url>
  </required_header>
  <id_info>
    <org_study_id>AML 01/99 trial</org_study_id>
    <nct_id>NCT00209833</nct_id>
  </id_info>
  <brief_title>Treatment of Adults Aged Up to 60 Years With De Novo Acute Myeloblastic Leukaemia,Secondary AML, or RAEB-T</brief_title>
  <official_title>Protocol for the Treatment of Adults Aged &lt;/= 60 Years With De Novo Acute Myeloblastic Leukaemia or Secondary AML or RAEB-T (AML 01/99 Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hannover Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Ulm</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johann Wolfgang Goethe University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Freiburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Klinikum Augsburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Humboldt-Universit채t zu Berlin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universit채tsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Ghent</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medizinische Universit채tsklinik T체bingen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Klinikum Hanover-Siloah Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ev. Krankenhaus Essen-Werden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Klinikum Wuppertal GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hannover Medical School</source>
  <brief_summary>
    <textblock>
      This randomized phase II/III trial investigates the antileukemic activity and toxicity of the
      FLAG-Ida regimen as a second induction course in patients with acute myeloid leukaemia and
      bad response to the first induction cycle and/or with a high risk karyotype and compares the
      antileukemic activity and toxicity of high dose cytarabine/daunorubicin vs. autologous
      peripheral blood stem cell transplantation as late consolidation therapy in standard risk
      patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Assessment of the antileukemic activity and toxicity of the FLAG-Ida regimen as a second
      induction course in patients with bad response to the first induction cycle and/or with a
      high risk karyotype.

      Optimization of the late consolidation therapy in standard risk patients (SR) by a
      prospective randomized trial comparing a high-dose cytarabine/daunorubicin (HD-Ara-C/DNR)
      based late consolidation therapy with an autologous peripheral blood stem cell
      transplantation (PBSCT)

      Assessment of the antileukemic activity of the different treatment elements by monitoring
      residual disease (MRD) after induction, early and late consolidation by Real-time PCR

      Assessment of the prognostic relevance of minimal residual disease by quantification of the
      residual leukemic burden in haematological remission by Real-time PCR during follow-up
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 1999</start_date>
  <completion_date>September 2005</completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy and toxicity of FLAG-Ida as second induction course in high risk patients.</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy and toxicity of high-dose cytarabin/daunorubicin (HD-Ara-C/DNR) based late consolidation therapy vs. autologous peripheral blood stem cell transplantation in standard risk patients.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Monitoring residual disease (MRD) after induction, early and late consolidation by Real-time PCR.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the prognostic relevance of minimal residual disease by quantification of minimal residual disease.</measure>
  </secondary_outcome>
  <enrollment>200</enrollment>
  <condition>De Novo Akute Myeloid Leukemia (AML)</condition>
  <condition>Secondary Acute Myeloid Leukemia (AML)</condition>
  <condition>Refractory Anemia With Excess of Blasts in Transformation</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idarubicin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-CSF</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daunorubicine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of de-novo AML, FAB M 1, 2, 4 - 7

          -  diagnosis of secondary AML after chemo-/radiotherapy or MDS

          -  diagnosis of RAEB-T

          -  age between 16 and 60 years (including 60 years)

          -  women after exclusion of pregnancy

          -  written informed consent

        Exclusion Criteria:

          -  patients with severe disease of the heart (e.g. cardial failure NYHA III/IV; history
             of myocardial infarction within the last 6 months;severe ventricular arrythmias (Lown
             III to IV)

          -  patients with DLCO &lt; 50%

          -  patients with creatinine clearance &lt; 60 ml/min

          -  patients with bilirubin &gt; 2mg% (34.2 mmol/L)

          -  patients with severe complications of the leukaemia such as uncontrolled bleeding,
             pneumonia with hypoxia or shock

          -  patients with a psychiatric, addictive, or any disorder which compromises ability to
             give truly informed consent for participating in this study

          -  HIV positivity

          -  patients with a t(15;17) translocation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arnold Ganser, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hannover Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hannover Medical School</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.kompetenznetz-leukaemie.de/</url>
  </link>
  <verification_date>September 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <last_update_submitted>November 17, 2005</last_update_submitted>
  <last_update_submitted_qc>November 17, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2005</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Anemia, Refractory</mesh_term>
    <mesh_term>Anemia, Refractory, with Excess of Blasts</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Idarubicin</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

